Literature DB >> 15719385

Can a leukocyte depletion filter (LDF) reduce the risk of reintroduction of hepatocellular carcinoma cells?

Mi Sook Gwak1, Kwang-Woong Lee, Shi Yeon Kim, Jihyun Lee, Jae Won Joh, Sung Joo Kim, Hwan Hyo Lee, Jean Wan Park, Gaab Soo Kim, Suk-Koo Lee.   

Abstract

During liver transplantation for hepatocellular carcinoma (HCC) patients, HCC could theoretically be introduced into the systemic circulation when salvaged blood is used with an autotransfusion device. Several reports have shown that some types of leukocyte depletion filters (LDFs) could completely reduce the risk for reintroducing some types of tumor cells. In this study, we tested the ability of the LDF (RCEZ1T, Pall Biomedical Co, NY, USA) to reduce the risk for reintroducing HCC cells in vitro by using a very sensitive detection method. We divided the test group into 6 groups: group I was 10 cells, group II was 20 cells, group III was 2 x 10(3) cells, group IV was 2 x 10(5) cells, group V was 2 x 10(6) cells, and group VI was 2 x 10(7) cells. The counted cells in 200 mL saline were passed through the RCEZ1T using the force of gravity. To identify the presence of cells, the pellet was resuspended, and polymerase chain reaction (PCR) was performed. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a housekeeping gene, was used as a primer. In groups I and II, the HCC cells were completely filtered in all experiments. However, in groups III, IV, and V, the HCC cells were not completely filtered in a few of the repeated experiments, with the unfiltered rate of tumor cells being between 8% and 20%. In group VI, the HCC cells were not completely filtered in all the repeated experiments. In conclusion, the RCEZ1T filter markedly reduced the risk for reintroduction of HCC cells. However, at high HCC cell load the filter cannot completely remove all the tumor cells. Further studies are required to assess the impact in clinical settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719385     DOI: 10.1002/lt.20346

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  French editorial from the ACHBPT: blood salvage and autotransfusion during liver transplantation for advanced hepatocellular carcinoma.

Authors:  Charlotte Maulat; Paul Boulard; Fabrice Muscari
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

2.  Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

Authors:  Naresh Kumar; Qasim Ahmed; Victor K M Lee; Aye Sandar Zaw; Raymond Goy; Hee Kit Wong
Journal:  Eur Spine J       Date:  2015-07-19       Impact factor: 3.134

3.  Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients.

Authors:  Sami Akbulut; Cuneyt Kayaalp; Mehmet Yilmaz; Volkan Ince; Dincer Ozgor; Koray Karabulut; Cengiz Eris; Huseyin Ilksen Toprak; Cemalettin Aydin; Sezai Yilmaz
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

4.  Irradiation Can Selectively Kill Tumor Cells while Preserving Erythrocyte Viability in a Co-Culture System.

Authors:  Ming Gong; Jin-Ting Yang; Yun-Qing Liu; Li-Hui Tang; Yin Wang; Lie-Ju Wang; Feng-Jiang Zhang; Min Yan
Journal:  PLoS One       Date:  2015-05-27       Impact factor: 3.240

5.  Effect of X-ray irradiation on hepatocarcinoma cells and erythrocytes in salvaged blood.

Authors:  Feng-Jiang Zhang; Jin-Ting Yang; Li-Hui Tang; Wen-Na Wang; Kai Sun; Yue Ming; Kanhar Ghulam Muhammad; Yin-Fei Zheng; Min Yan
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

6.  Survival analysis of intraoperative blood salvage for patients with malignancy disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Wei-Wei Wu; Wei-Yi Zhang; Wei-Han Zhang; Lei Yang; Xiao-Qian Deng; Meng-Chan Ou; Yao-Xin Yang; Hai-Bei Liu; Tao Zhu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

7.  Evaluation of riboflavin photochemical treatment for inactivation of HCT116 tumor cells mixed in simulative intraoperative salvage blood.

Authors:  Yang Yu; Lu Yang; Chunyu He; Shengfei Tai; Chunya Ma; Tianxin Yang; Deqing Wang
Journal:  Transfusion       Date:  2019-09-30       Impact factor: 3.157

8.  Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study.

Authors:  Andreas Winter; Kai Zacharowski; Patrick Meybohm; Andreas Schnitzbauer; Peter Ruf; Claudia Kellermann; Horst Lindhofer
Journal:  BMC Anesthesiol       Date:  2021-10-29       Impact factor: 2.217

9.  CTCs detection from intraoperative salvaged blood in RCC-IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study.

Authors:  Xiaoqing Zhang; Xiangyang Guo; Yanan Zong; Chuanya Xu; Jilian Wang; Bin Zhang; Chang Liu; Yueqing Gong; Lixiang Xue; Lulin Ma; Shudong Zhang; Yi Li; Hong Zeng
Journal:  BMC Urol       Date:  2021-06-10       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.